Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS ALT5 Sigma	$7.21 +3.6%	$7.93	$1.55 ▼ $10.95	$150.40M	2.17	5.70 million shs	16.35 million shs
ESLA Estrella Immunopharma	$0.87 +1.8%	$0.90	$0.63 ▼ $1.78	$31.50M	0.34	16,106 shs	2,230 shs
GLSI Greenwich LifeSciences	$12.08 +2.5%	$10.51	$8.06 ▼ $16.50	$157.48M	1.65	67,336 shs	99,641 shs
RAPT Rapt Therapeutics	$11.25 +6.1%	$9.66	$5.67 ▼ $26.56	$175.30M	0.01	107,123 shs	47,572 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS ALT5 Sigma	+3.59%	-11.86%	+0.56%	+6.03%	+321.64%
ESLA Estrella Immunopharma	+1.80%	+2.25%	+3.47%	-9.80%	-40.75%
GLSI Greenwich LifeSciences	+2.55%	+3.51%	+19.84%	+24.02%	-7.01%
RAPT Rapt Therapeutics	+6.13%	+9.76%	+6.03%	+67.71%	-34.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS ALT5 Sigma	0.617 of 5 stars	0.0	4.0	0.0	3.2	0.0	0.0
ESLA Estrella Immunopharma	3.1958 of 5 stars	3.5	5.0	0.0	3.3	1.7	0.0
GLSI Greenwich LifeSciences	1.4439 of 5 stars	3.5	0.0	0.0	2.0	1.7	0.0
RAPT Rapt Therapeutics	4.5874 of 5 stars	4.3	3.0	4.2	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,749.71% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	222.85% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$21.57	91.75% Upside

Current Analyst Ratings Breakdown

Latest ESLA, ALTS, RAPT, and GLSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/12/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $38.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS ALT5 Sigma	$12.53M	12.43	N/A	N/A	$0.55 per share	13.11
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
RAPT Rapt Therapeutics	$1.53M	121.62	N/A	N/A	$9.94 per share	1.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-74.89%	-179.27%	-16.28%	N/A
ESLA Estrella Immunopharma	-$7.31M	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-358.54%	9/26/2025 (Estimated)
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	N/A
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-67.92%	-59.59%	N/A

Latest ESLA, ALTS, RAPT, and GLSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.30	-$0.06	-$0.30	N/A	N/A
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS ALT5 Sigma	1.26	0.83	0.83
ESLA Estrella Immunopharma	N/A	0.22	0.22
GLSI Greenwich LifeSciences	N/A	1.91	1.91
RAPT Rapt Therapeutics	N/A	13.25	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS ALT5 Sigma	6.27%
ESLA Estrella Immunopharma	0.35%
GLSI Greenwich LifeSciences	4.16%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
ALTS ALT5 Sigma	4.90%
ESLA Estrella Immunopharma	55.10%
GLSI Greenwich LifeSciences	51.67%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS ALT5 Sigma	170	21.61 million	20.55 million	N/A
ESLA Estrella Immunopharma	N/A	37.07 million	16.24 million	Not Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

ESLA, ALTS, RAPT, and GLSI Headlines

Recent News About These Companies

Rapt Therapeutics price target raised to $9 from $8 at UBS

August 12 at 6:58 PM | msn.com

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

August 12 at 10:55 AM | zacks.com

HC Wainwright Issues Optimistic Forecast for RAPT Earnings

August 12 at 2:45 AM | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Lowered by Wall Street Zen

August 11, 2025 | americanbankingnews.com

HC Wainwright Issues Positive Forecast for RAPT Earnings

August 11, 2025 | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Rating Lowered to Sell at Wall Street Zen

August 10, 2025 | marketbeat.com

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1, 2025 | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31, 2025 | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30, 2025 | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30, 2025 | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from Analysts

July 23, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ESLA, ALTS, RAPT, and GLSI Company Descriptions

ALT5 Sigma NASDAQ:ALTS

$7.21 +0.25 (+3.59%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.32 +0.12 (+1.60%)

As of 08/14/2025 07:59 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Estrella Immunopharma NASDAQ:ESLA

$0.90 +0.05 (+5.80%)

As of 08/14/2025 04:00 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Greenwich LifeSciences NASDAQ:GLSI

$12.08 +0.30 (+2.55%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$12.12 +0.04 (+0.29%)

As of 08/14/2025 05:03 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Rapt Therapeutics NASDAQ:RAPT

$11.25 +0.65 (+6.13%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$11.24 -0.01 (-0.09%)

As of 08/14/2025 07:11 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time